Clinical Trial Update: Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating tislelizumab with afatinib for head and neck squamous cell carcinoma has completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: West China Hospital | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED